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Stem-loop real-time PCRncodes multiple microRNAs (miRNAs) from two primary transcripts, BHRF1 and
the BARTs. The expression of BHRF1 miRNAs is dependent on the type of viral latency, whereas the BART
miRNAs are expressed in cells during all forms of latency. It is not known how these miRNAs are otherwise
regulated, though. We have used quantitative, stem-loop, real-time PCR to measure the expression of EBV's
miRNAs and found them to differ nearly 50- and 25-fold among all tested cell lines and among EBV-positive
Burkitt's lymphomas, respectively. In addition, the expression of individual BART miRNAs within a cell can
differ by 50-fold or more despite the fact these miRNAs are likely transcribed together as a single primary
transcript. These measurements are illuminating: they indicate that few of EBV's miRNAs are expressed at
levels comparable to those of cellular miRNAs in most cell lines and therefore likely function
interdependently.
© 2009 Elsevier Inc. All rights reserved.IntroductionEpstein–Barr Virus (EBV) is a successful pathogen that infectsmore
than 90% of all adults in the world (Williams and Crawford, 2006).
While adapting to its host EBV has evolved properties that make it
particularly interesting to study. It maintains its DNA as a licensed,
extra-chromosomal replicon. This viral replicon is present in clonally
derived cells with a wide distribution of numbers of DNA molecules
per cell (Nanbo et al., 2007). Failures in its synthesis and faithful
partitioning drive these distributions both to increase and decrease
the numbers of DNA molecules per cell during cellular proliferation
(ibid.). This property means that the templates encoding viral genes
vary widely in otherwise genetically identical cells and raises the
general question of how the expression of these genes is controlled. A
second recently appreciated property of EBV is that it encodes about
30 mature miRNAs from 20 pre-miRNAs which, given the size of its
genome (approximately 165 kbp), represents a thousand-fold
enrichment of this class of genes relative to those in its human host
(Cai et al., 2006; Grundhoff et al., 2006; Landgraf et al., 2007; Pfeffer et
al., 2004). MiRNAs function dose-dependently with two-fold differ-
ences in their levels having signiﬁcant biological consequences
(Raveche et al., 2007; Xiao et al., 2007). That EBV encodes such a
relatively high number of miRNAs indicates its evolutionary selectionen).
, P.O. Box 7365, Madison, WI,
ll rights reserved.for them and raises the question of how the expression of these
particular viral genes is controlled.
EBV's miRNAs are encoded in two primary transcripts, the BHRF1
transcript which also encodes the BHRF1 orf and the BamHI A
rightward transcripts (BARTs) which are a set of long, alternatively
spliced transcripts,whichmayencode the BARF0 orf (Fig.1). TheBARTs
contain two clusters ofmiRNAs, which have been termed Cluster 1 and
Cluster 2 (Fig. 1). Some of these miRNAs have been characterized by
their being cloned; some have been detected by Northern blotting;
while others have been predicted by various computational
approaches (Cai et al., 2006; Grundhoff et al., 2006; Landgraf et al.,
2007; Pfeffer et al., 2004). These analyses have detected different
signal intensities of EBV's miRNAs in Northern blots but have not
determined the numbers of molecules in the various cells studied. We
therefore have used stem-loop real-time PCR and synthetic standards
to quantify the average number of EBV's miRNAs in 17 cell lines under
various conditions. We have assayed miRNAs encoded by the BHRF1
transcript and the BARTs to identify the conditions under which they
are co- or differentially regulated. We have also measured the levels of
the miRNAs following infection of primary B-cells by EBV and in cell
lines induced to support the viral lytic cycle in order to elucidate their
regulation throughout the viral life-cycle.
Our measurements indicate that the primary transcripts encoding
EBV's BARTmiRNAs likely encode an intrinsic mode of regulation such
that the rank order of individual miRNAs between cells is similar.
These relative levels, for example, are recapitulated when a primary
transcript encoding most BART miRNAs is expressed from a retroviral
vector in EBV-negative cells. The measurements show also that the
absolute levels of the miRNAs vary by up to 50-fold between cell types
Fig. 1. EBV's miRNAs are processed from two transcripts. The mRNA encoding BHRF1 encodes BHRF1-1 in the 5′ untranslated region (UTR), and BHRF1-2 and BHRF1-3 are encoded in
the 3′ UTR of the transcript. The BARTs encode 28 miRNAs found in two clusters. BART Cluster 1 encodes 11mature miRNAs from 8 pre-miRs in a 1 kb region, whereas BART Cluster 2
encodes 15maturemiRNAs from 11 pre-miRs in a 3 kb region. The two clusters are separated by 5 kb. BART2 is encoded near the end of the genome, encodes twomaturemiRNAs, and
is complementary to BALF5, the EBV lytic DNA polymerase. In the B95-8 strain of EBV a 14 kb region of the BARTs encoding six BART Cluster 1 miRNAs and all BART Cluster 2 miRNAs
are deleted.
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These ﬁndings make it likely that the expression of EBV's miRNAs is
regulated intrinsically by their primary transcripts and likely also by
the efﬁciency of transcription of those primary transcripts.
Results
EBV's BART miRNAs accumulate to different levels among EBV-infected
cell lines
It has been shown that the levels of BART miRNAs probably differ
in EBV-positive BLs (Cai et al., 2006; Edwards et al., 2008; Lo et al.,
2007; Pfeffer et al., 2004; Xia et al., 2008).Wewanted tomeasure both
the number of individual miRNAs within one cell line and their
numbers between cell lines. These numbers would help determine
which mRNAs could be targeted by EBV's miRNAs and the extent to
which given mRNAs could be regulated by the viral miRNAs. We used
stem-loop, quantitative, real-time PCR (qPCR) to measure eight BART
miRNAs and the BHRF1-3 miRNA along with known quantities of
syntheticmiRNAs identical to thematuremiRNA sequence to generatestandard curves for these experiments. The miRNAs analyzed were
selected to span the range of levels of expression derived from
published Northern blots (Cai et al., 2006; Edwards et al., 2008;
Grundhoff et al., 2006; Lo et al., 2007). We assayed six kinds of EBV-
infected cells to uncover possible relationships between the structure
of the viral genome, its overall pattern of transcription, and the
steady-state levels of viral miRNAs. These cell lines included ones with
large deletions within the coding regions for BART Cluster 1 and
Cluster 2 (B958IID6 and 721) (Fig. 1); Type I BLs which express the
fewest viral genes among EBV-positive tumors (Akata, BL-5, Dante,
KemI, MutuI, and SavI); Type III BLs which have evolved upon
propagation in cell culture to express additional viral genes found in
type III latency (MutuIII and Raji); variant BLs with deletions in EBNA2
(Daudi, OkuI, and GG68); and carcinoma cell lines (C666-1 and
SNU719). The numbers of molecules of each miRNA per 10 pg of total
RNA were determined in 17 EBV-positive cell lines (Fig. 2). No miRNA
was detected at more than 1 molecule per 10 pg of total RNA in the
EBV-negative BL cell line, BJAB (data not shown). We chose to
compare the number of miRNA molecules per unit of total RNA mass
because different amounts of total RNA were isolated per cell among
Fig. 2. Some EBVmiRNAs are expressed in all tested EBV-positive cell lines, but do not accumulate to the same steady-state levels. B95-8 infected LCLs (A), type I BLs (B, D, E), type III BLs
(C,D), and recombinantEBV (D), PTLD (D),NPC (E), andgastric carcinoma(E) cell lineswere assayed for their steady-state levelsof oneBHRF1miRNAandeight BARTmiRNAsby stem-loop
qPCR.We alsomeasured the expression of EBVmiRNAs in a BJAB clone,which conditionally expresses EBV's BART Cluster 2miRNAs (A). Steady-state levels of eachmiRNAwere calculated
bygenerating standard curveswith knownquantities of syntheticmiRNAs identical to thematuremiRNAsequence. Eachﬁgurehas adifferent range on they-axis dependingon the levels of
the miRNAs in the cell lines assayed. The error bars for BHRF1-3 and BARTs 3, 1-5p, 7, and for all cell lines in (A), Raji and MutuIII (C), OkuI (D), and Dante and C666-1 (E) represent the
standard deviation of the average of two independent experiments, each consisting of triplicate qPCR measurements. For Akata eGFP (D), all miRNAs were measured in more than one
independent experiment. The sampleswithouterror bars are the average of triplicate qPCRmeasurements fromone experiment. BARTmiRNAs are shown in the order as theyappear in the
wild-type EBV genome. BARTs 3, 4, 1-5p, and 15 are encoded by BART Cluster 1, and miR-BARTs 7, 10, 12, and 20-5p are encoded by BART Cluster 2.
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a miRNA per 10 pg of RNA, we compared the expression of each
miRNA in relation to all RNAs in the cell, which may be a more
accurate measurement for the activity of a miRNA than total number
per cell. We were able to detect both mature BART15 and BART20-5p,
which have been largely undetected by Northern blot (Grundhoff et
al., 2006; Lo et al., 2007). BART15 was expressed at levels similar to
BART1-5p, where BART20-5p was consistently the least well
expressed of all the BART miRNAs assayed.
BHRF1-3 accumulated in cells in which EBV exhibited a type III
latency (Figs. 2A, C, D) and was also detected in ﬁve BL cell lines not
known to express BHRF1 miRNAs (Figs. 2B, D, 4A). OkuI cells ex-Fig. 3. The expression of EBV's BART miRNAs differ among EBV-positive cell lines. The stead
average levels of that BART miRNA across 15 cell lines maintaining full-length EBV. Shown is
represent the standard deviation of the average expression for the eight assayed BART miRpressed BHRF1-3 at similar steady-state levels to type III BLs (∼200
molecules per 10 pg of total RNA), while BL-5, KemI, Daudi, and Akata
all expressed BHRF1-3 at one-ﬁfth or less the levels of type III BLs.
The steady-state levels of BART miRNAs differed among EBV-
positive cell lines. Expression of each miRNA was normalized to the
expression across all cell lines maintaining the full-length EBV
genome (Fig. 3). In agreement with what has been previously
estimated with Northern blots, EBV BART miRNAs were differentially
expressed among cell lines. We found the levels of expression of BART
miRNAs to be greatest in the NPC cell line, C666-1, and the gastric
carcinoma cell line, SNU719. Those in C666-1 were at least two-fold
greater than in any of the BL cell lines tested (Fig. 3). On average, they-state levels of each BART miRNA assayed by stem-loop qPCR were normalized to the
the average normalized expression for the eight assayed BART miRNAs. The error bars
NAs.
Fig. 4. Three BLs that spontaneously lose EBV in culture express low levels of BART
miRNAs, but do not have a general defect in transcription. MutuI, Akata, and Daudi cells
were assayed for expression of BHRF1-3 and eight BARTmiRNAs by stem-loop qPCR (A).
To conﬁrm expression was not a general defect in transcription, EBNA1 protein
expression (B) was measured by western blot, and expression of the EBV non-coding
RNAs, EBER1 and EBER2, was measured by qPCR (C). Expression of EBER1 and EBER2
was normalized to the expression of the cellular mRNA, GAPDH.
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abundant than in Daudi cells (Fig. 3). Even in comparing BL cell lines
we saw a 25-fold greater expression of BART miRNAs in KemI than in
Daudi cells, which are the BLs that express the most and least miRNAs,
respectively. The Akata eGFP was found to express BART miRNAs 7-
fold greater on average than Akata. This difference likely reﬂects
Akata's evolving to lose its EBV and Akata eGFP being a derivative of
Akata which had lost EBV and into which EBV was newly introduced.
The original EBV genomes in Akata likely accumulated methylations
and possibly other forms of epigenetic regulation not shared by the
EBV newly introduced into Akata eGFP.
Although the absolute levels of EBV's BART miRNAs differ among
EBV-infected cell lines, the ranked order of the levels of individual
BART miRNAs are similar among these cell lines
Measuring the eight assayed BARTmiRNAs revealed that though the
genomic locations of these miRNAs are clustered, their steady-state
levels differ from each other in different cell lines. For instance, C666-1
cells expressed BART7 at 6-fold greater levels than BART12, and 50-fold
greater than BART20-5p, all three being encoded in BART Cluster 2.
BART7′s expression was at least two-fold greater than any assayed
miRNA encoded by BART Cluster 1 (Fig. 2E). BART20-5p consistently
had the lowest steady-state levels, while BART7 and BART10 were
among the highest in all assayed EBV-positive cell lines (Fig. 2).
These measurements demonstrated that EBV-positive cells appa-
rently express their different miRNAs relative to each other similarly.
To test this possibility, each of the eight assayed BART miRNAs was
ranked based on its steady-state levels in each cell line, and then
compared to the ranked expression of the same eight BART miRNAs in
all other assayed cell lines. The ranked order of expression of the eight
assayed BART miRNAs was statistically signiﬁcant for 90 of 105 (86%)
pairwise comparisons (Spearman rank correlation, pb0.05, Supple-
mentary Fig. 1). The rank order of this expression is independent of
cell type; epithelial cell lines and B cell lines both exhibit a similar rank
order. This analysis shows that the ranked orders of the steady-state
levels of BART miRNAs in most EBV-positive cell lines are similar.
This conclusion is conﬁrmed in the studies of the 721 and B958IID6
cells which are both immortalized by the B95-8 strain of EBV. This
strain contains a 14 kbp deletion in the BARTs that removes the coding
sequence for part of BART Cluster 1 and all of the Cluster 2 miRNAs
(Fig. 1). In these cells, the coding sequence for BARTs 3, 4, 1-5p and 15
are all retained. As with the full-length virus, BART4 was expressed at
the lowest levels, whereas expression of BARTs 3, 1-5p, and 15 were
similar to each other (Fig. 2A). Thus the ranked order of expression of
EBV's BART miRNAs is maintained even when a large portion of the
DNA encoding the primary transcript for the BARTs is deleted. That the
relative levels of individual viral miRNAs is similar between cell lines
is also supported by our expressing BART Cluster 2, which is deleted in
the B95-8 strain of EBV, in the EBV-negative cell, BJAB. The order of the
steady-state levels of these miRNAs encoded by Cluster 2 in BJAB cells
is similar to that in most EBV-positive cell lines (Fig. 2A).
Three BLs that spontaneously lose EBV express the BART miRNAs less
efﬁciently than do the BLs that maintain EBV stably
Three EBV-positive BL cell lines expressed surprisingly low levels
of the individual BART miRNAs. These cell lines, Akata, MutuI, and
Daudi all spontaneously lose EBV in cell culture (Kitagawa et al., 2000;
Nanbo et al., 2002; Shimizu et al., 1994). The levels of miRNAs
expressed by these cells are so low that measuring their relative levels
becomes difﬁcult (Fig. 4A). In contrast, the type III derivative of MutuI,
MutuIII, whichmaintains EBV in culture, had on average 2.5-foldmore
of each BART miRNA than did MutuI cells (Fig. 3). We tested if these
low levels of miRNAs result from some cells having already lost their
EBV genomes. By FISH 90%, 98%, and 84% of Akata, MutuI, and Daudicells were EBV-positive, respectively, at the time of RNA isolation.
Thus the observed low steady-state levels of BART miRNAs in these
cell lines did not result from the cells having lost EBV. We asked
whether the inefﬁcient expression of BART miRNAs in these cell lines
was speciﬁc to the miRNAs, or reﬂected a general defect in trans-
cription. Expression of EBNA1 protein was measured in the Daudi,
MutuI, and Akata cell lines and compared to expression in EBV-
positive cell lines that do not lose EBV spontaneously (Fig. 4B). Both
Daudi and MutuI cells expressed EBNA1 at levels similar to other BL
cell lines. We could not detect EBNA1 in the Akata cells with our
antisera although it has been shown to be expressed normally in
earlier studies (Komano et al., 1998).We alsomeasured the expression
of the EBV non-coding EBERs, EBER1 and EBER2 by qPCR (Fig. 4C). All
Fig. 5. Steady-state levels of BART miRNAs are not determined by the number of viral
templates per cell. Eight EBV-positive BL cell lines were assayed for the number of
genomes per cell by FISH, and for the levels of BART miRNAs by stem-loop qPCR. Cell
lines are ordered left to right in increasing number of viral templates. The average
normalized expression for eight assayed BART miRNAs is shown as in Fig. 3. The error
bars represent the standard deviation of the average normalized expression.
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to cell lines that efﬁciently expressed BART miRNAs. The inefﬁcient
expression of BART miRNAs in Akata, Daudi, and MutuI cells therefore
is not caused by a general defect in the expression of other viral genes.
This ﬁnding raises the possibility that BART miRNAs provide a
selective advantage to EBV-positive lymphomas that retain EBV but
not to those that lose the virus. Raji cells, which have not been shown
to lose EBV in culture, also have low levels of EBV's BART miRNAs
(Figs. 2C, 3). The origin of viral DNA synthesis used primarily in Raji
cells is located within the BART locus which may limit expression of
this locus (Norio et al., 2000; Wang and Sugden, 2008).Fig. 6. EBV BART miRNAs do not correlate with the expression of viral templates in lytic
expression upon lytic induction. Akata eGFP and B958ID6 cells were induced to support lytic r
Akata eGFP cells were harvested at 24, 49, 72, and 91 hpi. Expression of the BHRF1 (A) a
expression of BHRF1 (B), BART Cluster 1 (D), and BART Cluster 2 (F) miRNAs were measured
cells until 24 hpi. The relative number of viral templates present in induced B958IID6 and Ak
measurements are shown in black.The steady-state levels of BART miRNAs are not determined by the
number of viral templates per cell
The wide variation in the average normalized expression of viral
miRNAs in different B cell lines led us to ask if these levels correlated
with the average number of viral genomes per cell. Eight EBV-positive
BL cell lines that stably maintain the virus were assayed for their
number of viral genomes per cell by FISH and compared to the average
normalized, steady-state levels of the eight assayed BART miRNAs. The
steady-state levels of the BART miRNAs did not correlate with the
average number of viral templates (Fig. 5, Spearman rank correlation,
pN0.05). This was also true when we compared the number of viral
templates to the expression of the BART miRNAs on a per cell, rather
than per 10 pg of RNA (data not shown, Spearman rank correlation,
pN0.05). Raji, which has the greatest number of viral genomes, had the
lowest steady-state levels of miRNAs among the assayed cell lines.
Dante and BL-5 cell lines had the same number of viral templates per
cell, but Dante expressed on average three-fold greater levels of each
assayedBARTmiRNAthandid BL-5 cells. BothGG68andOkuI cells had a
third the number of the genomes as did BL-5, but on average expressed
similar levels of each assayed BART miRNA per cell. Finally, SavI, GG68,
andOkuI cells had similar distributions of the number of viral templates
per cell, but SavI expressed on average nearly three-fold more of the
eight assayed BART miRNAs than did GG68 and OkuI cells.
We were surprised to ﬁnd that Raji contained on average 230 viral
genomes per cell. This is nearly 5-fold higher than previously reported
by qPCR (Huang et al., 2003).We conﬁrmed that the cellswere Raji with
PCR by amplifying the region spanning the EBNA3C deletion identiﬁed
previously in Raji EBV (Hatfull et al., 1988 and data not shown).Akata eGFP or B958IID6 cells. However, BHRF1 miRNAs in Akata eGFP do increase in
eplication. B958IID6 cells were harvested at 22, 47, 70, and 93 h post induction (hpi) and
nd BART (C) miRNAs in B958IID6 cells were measured by stem-loop qPCR. Likewise,
in induced Akata eGFP cells. BHRF1-1 was not detected above background in Akata eGFP
ata eGFP cells is shown (E). B958IID6 measurements are shown in gray, and Akata eGFP
Fig. 7. EBVmiRNAs increase in expression during the ﬁrst 8 days post infection (dpi) of primary B cells, and are detected as early as 2 dpi. Expression of BHRF1-3 (A) and BARTmiRNAs
in primary B cells infected with Akata (B, black lines) or B95-8 (C, gray lines) EBV was measured during the ﬁrst 8 dpi. BART15 was not detected in cells infected with B95-8 EBV until
2 dpi (C). At 8 dpi, expression of BHRF1 miRNAs (D) and eight BART miRNAs (E) was measured.
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during productive infection
The absence of a correlation between the number of viral
templates in BLs during latent infection and their expression of viral
BART miRNAs led us to ask if the large increase in the numbers of viral
DNA molecules in cells supporting the lytic cycle would affect
expression of the miRNAs. Two EBV-positive cell lines, Akata and
B958 were induced to support their lytic cycle, and the levels of eight
BART and all 3 BHRF1 miRNAs were measured for 93 h post induction
(hpi). The levels of BART miRNAs remained unchanged in cells
induced to support the lytic cycle, though the number of available viral
templates increased nearly 50-fold in both cell lines (Figs. 6C–F).
BART7, which is deleted in B958, was not detected above background
upon induction of lytic replication in this cell line (data not shown).
The levels of the BHRF1 miRNAs in the B958 cells remained
unchanged, while their levels increased between 4- and 20-fold in
the induced Akata cells (Figs. 6A, B). The levels of expression of the
three BHRF1 miRNAs in the induced Akata cells were much lower,
however, than those found in BLs that exhibit type III latency (Figs. 2A,
6B). The BHRF1 miRNAs are thus regulated differently in the B958 and
Akata cells either because of the different viral strains or their diffe-
rent host cells.
The expression of EBV BART miRNAs increases over the ﬁrst 8 days
post infection
We measured when during infection of primary B cells EBV
miRNAs are expressed. Primary B cells were infected with either the
B95-8 or the Akata strain of EBV at an MOI of 1, cells were harvested at
1, 2, 4, and 8 days post infection (dpi), and assayed for their expression
of miRNAs (Fig. 7). These miRNAs were detectably expressed by 2 dpi,
and increased in expression throughout the ﬁrst 8 dpi (Figs. 7A–C).
In an independent experiment, where we used a miRNA microarray
with probes to EBV's miRNAs to detect expression of the viral miRNAs,
expression of EBV's miRNAs could be detected 10-fold above back-ground 20 h post infection (data not shown). Not surprisingly, BART7
was expressed at the highest level in Akata EBV-infected cells
(Fig. 7D). BART7 was not detected above background in cells infected
with B95-8 EBV (data not shown).We observed that the BARTmiRNAs
in Akata EBV-infected cells were expressed in a similar ranked order as
are established cell lines thatmaintain EBV (Fig. 7D). Themature BART
and BHRF1 miRNAs were expressed as early as 2 dpi, and thus could
affect regulation of viral and host genes at the beginning of the viral
life-cycle.
Raji EBV does not express mature BHRF1-3 because of a mutation in
its precursor-miRNA
Raji cells, which exhibit type III latency, did not express detectable
levels of BHRF1-3. We assayed the three BHRF1 miRNAs by stem-loop
qPCR in various EBV-positive cell lines that were found to express
BHRF1-3 to determine if Raji's apparent failure to express this viral
miRNAwas exceptional. While all cell lines assayed expressed BHRF1-1
and BHRF1-2, only Raji failed to express BHRF1-3 detectably (Fig. 8A).
We analyzed this defect by isolating a 2.5 kb fragment of EBV DNA
containing the BHRF1 mRNA coding sequence from both 721 and Raji
cells, cloned, and sequenced these DNAs. There was a single
nucleotide mutation in Raji EBV that mapped to the predicted stem
sequence of the BHRF1-3 precursor-miRNA (pre-miR), introducing an
A:C mismatch in place of a G:C base pair (Fig. 8B). This mutation was
conﬁrmed by independently amplifying and sequencing the Raji EBV a
second time. Mfold (Mathews et al., 2007; Zuker, 2003) predicted that
the A:C mismatch in Raji EBV would disrupt base-pairing near the
base of the stem-loop structure of pre-miR-BHRF1-3, shortening the
length of the pre-miR stem, and making it likely to inhibit its
maturation (Fig. 8C). We tested whether this mutation affected the
processing of BHRF1-3 by reverting the mutation in pre-miR-BHRF1-3
of Raji EBV to that of the B95-8 sequence by site-directedmutagenesis.
Vectors encoding the three BHRF1 miRNAs from Raji EBV DNA
(Mutant), from B95-8 EBV DNA (Wt), and the reverted sequence
(Wt⁎) were introduced into 293 cells. While the mature BHRF1-3 was
Fig. 8. Raji EBV does not express detectable BHRF1-3. Expression of BHRF1 miRNAs in Raji, 721, MutuIII, OkuI and B958IID6 (B958) cell lines was measured by stem-loop qPCR1 (A).
Error bars represent the standard deviation of the average expression from at least two independent measurements. Sequence alignment of the wildtype and Raji revealed a single
nucleotide mutation in the genomic region encoding pre-miR-BHRF1-3 (B). The mature miRNA sequence is underlined, and the mutation is indicated by an arrow. (C) The stem-loop
structures of thewildtype and Raji pre-miR-BHRF1-3 were predicted byMfold (C). Themature BHRF1-3 sequence is highlighted in red, and themutation is indicated by an arrow. The
steady-state levels of the BHRF1 miRNAs were measured in 293 cells transfected with vectors encoding the BHRF1 sequence from B95-8 EBV (Wt), Raji EBV (Mutant), or Raji EBV in
which the mutation in the pre-miR-BHRF1-3 was reverted to the Wt sequence (Wt⁎) (D). Transfection efﬁciencies of each vector were determined to be 6.5–9% by calculating
percentage of GFP positive cells 48 h post transfection. Expression of BHRF1 miRNAs was assayed by stem-loop qPCR from total RNA isolates. The number of molecules per 10 pg for
BHRF1-3 in the three transfections are listed above the BHRF1-3 bars. Background levels for BHRF1-3 were found to be less than one copy per cell in EBV-negative BJAB cells. Error
bars represent the standard deviation of duplicate experiments.
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Raji-derived vector, it was expressed from the reverted Raji-derived
vector (Fig. 8D). BHRF1-3 was measured at an approximately 50-fold
higher level than the limit of detection in cells transfected with the
reverted sequence as compared to the Raji-derived vector, indicating
that the mutation detected in Raji cells underlies this strain of EBV's
defect in expressing this miRNA. Thus for strains of EBV with
functional BHRF1 miRNA genes, the three genes are expressed
coordinately.
Discussion
EBV's miRNAs have been detected by Northern blotting or cloning
(Cai et al., 2006; Grundhoff et al., 2006; Landgraf et al., 2007; Pfeffer
et al., 2004). Among these, BART7, 10, and 12 have been most
frequently detected and BART15 and 20-5p rarely or not at all (Cai
et al., 2006; Edwards et al., 2008; Grundhoff et al., 2006; Kim do et al.,
2007; Lo et al., 2007). We have used stem-loop real-time PCR along
with synthetic miRNAs to quantify these ﬁve viral miRNAs and six
additional ones in a biologically diverse set of cell lines to determine
their levels of accumulation within and between these cell lines.
These measurements indicate the two sets of viral miRNAs
expressed from individual primary transcripts, the BHRF1 miRNAs
and the BART miRNAs, are each expressed coordinately. Generally all
three BHRF1 miRNAs are expressed or none is; all BART Cluster 1 and
Cluster 2 miRNAs are expressed or none is. An apparent exception to
this generalization was the BHRF1-3 miRNA in Raji cells which failed
to be expressed while the other two BHRF1 miRNAs were. This excep-
tion was explained by ﬁnding a mutation in the coding region for the
pre-miRNA of BHRF1-3 which would likely prevent its processing
(Fig. 8). Another exception was in cell lines immortalized with theB95-8 strain of EBV, which is explained by the absence of sequence
that encodes all of BART Cluster 2 and part of BART Cluster 1 (Fig. 2A).
Secondly, BHRF1 miRNAs are thought to arise from the Cp
promoter in type III latency (Cai et al., 2006). Transcripts from this
promoter encode the EBNA proteins and the miRNAs in these
transcripts would be located in known introns (Austin et al., 1988).
Based on recent evidence, such transcripts could co-express the
EBNAs, and the BHRF1 miRNAs (Kim and Kim, 2007). However, we
were able to detect BHRF1-3 above background levels in four cell lines
characterized as type I BLs (Fig. 2). It is not clear where transcripts
encoding BHRF1-3 originate in these cells, but they could arise from
the BHRF1 transcript which has been shown to be transcribed during
latency in some EBV-positive BL cell lines (Austin et al., 1988).
A third ﬁnding of these analyses is that levels of the individual
BART miRNAs differ by 50-fold or more within a cell line even though
they are processed from one primary transcript. This wide variation is
preserved between cell lines: BART7, for example, accumulates to the
highest levels and BART20-5p to the lowest levels for most cell lines
studied (Fig. 2). The steady-state levels of these miRNAs reﬂect their
rates of synthesis and degradation. Given that they are all processed
from one primary transcript the contribution to their steady-state
levels by their synthetic rates would be determined at least in part by
their processing. The differential expression of EBV's BART miRNAs
may be explained by the tertiary structure of their primary-miRNA
(pri-miR). Steven Chaulk and colleagues have found the individual
miRNAs in the human miR-17-92 cluster are differentially expressed,
with those expressed more efﬁciently having their stem-loop
structures located on the outside of the pri-miR structure and being
more accessible for processing by the microprocessor (S. Chaulk and J.
N. M. Glover, submitted for publication). In this model, of the BART
miRNAs we assayed, BART7 would be the most accessible to
Table 1
Cell type, EBV status, and latency type of cell lines used in this study
Cell line Cell type EBV status Latency type Reference
BJAB BL − − (Menezes et al., 1975)
MutuI BL + I (Gregory et al., 1990)
Daudi BL + I (Kitagawa et al., 2000)
Akata BL + I (Takada et al., 1991)
OkuI BL + I (Kelly et al., 2002)
SavI BL + I (Kelly et al., 2002)
KemI BL + I (Kelly et al., 2002)
Dante BL + I (Leao et al., 2007)
BL-5 BL derived from
HIV-positive donor
+ I (Lee et al., 1999)
Akata eGFP Recombinant BL + I (Kanda et al., 2004)
SNU719 Gastric carcinoma + II (Han et al., 2004)
C666-1 NPC + II (Cheung et al., 1999)
721 LCL + III (Kavathas et al., 1980)
B958IID6a LCL + III (Miller et al., 1975)
GG68 BL + III (Weigel and Miller, 1983)
Raji BL + III (Pulvertaft, 1965)
MutuIII BL + III (Gregory et al., 1990)
PTLD1 PTLD + III Gift from C. Rooney
a Clonal derivative of B95-8.
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is also possible that the stability of individual pre-miRs, which has
been used to predict pre-miRs in silico, may contribute to the steady
state levels of EBV's BART miRNAs (Brameier and Wiuf, 2007; Pfeffer
et al., 2004; Sewer et al., 2005).
A fourth ﬁnding of these analyses is that the absolute levels of
EBV's miRNAs vary by 50-fold or more between cell lines (Fig. 3). This
ﬁnding is important functionally because the levels of miRNAs in cells
will determine their capacity to target speciﬁc mRNAs: the concen-
tration of a given miRNA will affect its concentration in the RISC
complex and the frequency with which that complex encounters a
given mRNA. For example, the translation of c-Myb is less efﬁciently
inhibited by miR-150 in B-cells in mice heterozygous for this miRNA
than in those cells in wild-type animals carrying two copies of the
gene encoding this miRNA (Xiao et al., 2007). Three studied cell lines
were outliers with exceptionally low levels of miRNAs (Fig. 4A). These
three, Daudi, MutuI, and Akata have all been found to lose EBV DNA
spontaneously showing that EBV affords these cell too little selective
advantage to be retained in cells in culture. These cell lines do not
express other viral genes at disproportionately low levels raising the
possibility that the BART miRNAs encode functions most BLs require
and that Daudi, MutuI, and Akata cells have evolved to no longer
depend on functions of these miRNAs (Figs. 4B, C).
The levels of EBV's miRNAs not only differ widely between cells but
also are not correlated with the number of possible DNA templates
encoding them (Fig. 5). This ﬁnding could be explained by only a
subset of viral DNA molecules in infected cells functioning as
templates for transcription. One consequence of this hypothesis is
that it would explain how the individual cells within a clone which
have a wide distribution of viral DNA molecules per cell regulate their
expression of viral genes: only a subset of viral DNAs are transcribed.
It is clear that when EBV's lytic cycle is induced, there is little or no
increased expression of its miRNAs (Fig. 6). Apparently EBV does not
regulate its productive cycle by altering the levels of its miRNAs.
Clearly one likely exception to this conclusion is BART2, which we
have not examined but which is proposed to regulate EBV's
polymerase gene (Barth et al., 2008).
We have found that even for those of EBV's miRNAs which are
highly expressed, most are present at 100's of molecules per cell while
a few rise maximally to 1000–2000 molecules per cell in carcinoma
cell lines (Fig. 2). In contrast, individual cellular and viral miRNAs
which have been associated with functions are often present at
10–100,000 molecules per cell. For example, miR-155 accumulates to
levels of 2–10,000 per cell in diffuse large B-cell lymphomas where it
may contribute to B-cell tumorigenicity (Costinean et al., 2006; Eis
et al., 2005). Three of HSV-1's miRNAs are found at only 100's of
molecules per cell in lytic infection, but accumulate to 100,000s
per cell in neurons where they are thought to contribute to latency
(Umbach et al., 2008). Even the abundantly expressed BART7 and
BART10 are present at lower levels than human miR-16, which has
been measured to range from 500 to 50,000 molecules per 10 pg of
RNA in primary BLs and BL cell lines (Landgraf et al., 2007). One
possible explanation for EBV's relatively low numbers of individual
miRNAs is that they act together to target single mRNAs important for
EBV's life-cycle and likely important for its functions of tumor
maintenance, too. This explanation is consistent with experiments
showing that multiple miRNAs can act additively or synergistically to
regulate the same targeted mRNA (Grimson et al., 2007).
Materials and methods
Plasmid construction
The BHRF1 fragment of EBVwas ampliﬁed via PCR from 721 (Wt) or
Raji (Mutant) genomic DNA, (Forward primer 5′-ATGTAC GCG TTC ACT
AGC CAC TAAGCC-3′ and reverse primer 5′-GCTACT CGAGGT TGA AATATC TAG CAC GGC-3′) and then digested with MluI and XhoI. This
productwas ligated into themultiple cloning site (MCS) of the retroviral
plasmid MCS-IRES-eGFP, which was also digested with MluI and XhoI.
QuikChange (Stratagene)was used to revert speciﬁcally themutation in
pre-miR-BHRF1-3 derived from Raji to the wild-type sequence (Wt⁎)
using the forward primer 5′-GCG GTG CTT CAC GCT CTT CGT TAA AAT
AAC ACA AGG-3′ and reverse primer 5′-CCT TGT GTT ATT TTA ACG AAG
AGC GTG AAG CAC CGC-3′. QuikChange was again used to mutate the
ﬁrst start codon (ATG) of the BHRF1 protein coding sequence to ATC in
all threevectors using as a forwardprimer 5′-CCAGATCTTGTAGAGCAA
GAT CGC CTA TTC AAC AAG GG-3′ and as a reverse primer 5′-CCC TTG
TTG AAT AGG CGA TCT TGC TCT ACA AGA TCT GG-3′. All PCR fragments
were veriﬁed by restriction enzyme digestion and sequencing.
To clone the BART Cluster 1 vector, genomic DNA from Akata cells
was PCR ampliﬁed with forward primer 5′-TTG CTG AGC TAT CCT AGA
GGT CCT ACC G-3′ and reverse primer 5′-CCT TCG AAC TGT GGT TAC
ATG GTG CAT TTG C-3′ speciﬁc to the BARTs. The ampliﬁed product
contained nucleotides 138997 to 140144 of EBV (GenBank accession
no. AJ507799), and contains all currently known BART Cluster 1
miRNAs annotated in miRBase (Grifﬁths-Jones, 2004; Grifﬁths-Jones
et al., 2006, 2008). The ampliﬁed product was cut with BlpI and BstBI
restriction enzymes, and ligated into the MCS of the parent retroviral
plasmid tet-inducible-MCS-IRES-eGFP vector which was also cut with
BlpI and BstBI.
BART Cluster 2 vector was also cloned using genomic DNA from
Akata cells. Akata DNAwas PCR ampliﬁed with forward primer 5′-AAT
TCGAATAGGTCACCTAACGTGGAAGCC-3′ and reverse primer 5′- GTA
CGC GTT GTC CTT CTG TCA CAA CC -3′. The ampliﬁed product includes
nucleotides 145770 to 149022 of EBV (GenBank accession no.
AJ507799), and contains all currently known BART Cluster 2 miRNAs
as annotated in miRBase (Grifﬁths-Jones, 2004; Grifﬁths-Jones et al.,
2006, 2008). The ampliﬁed product was cut with BstBI and MluI
restriction enzymes, and ligated into the MCS of the parent retroviral
plasmid tet-inducible-MCS-IRES-eGFP vector which was also cut with
BstBI and MluI.
Cell lines, culture conditions, and RNA isolation
The cell lines used in this study, their EBV status and type of latency
are listed in Table 1. The B cell lines, including BLs, PTLDs, and EBV-
positive lymphoblastoid cell lines (LCLs) were cultured in RPMI 1640
(Invitrogen) supplemented with L-glutamine, 10% fetal bovine serum
(FBS), and antibiotics (200 U/mL penicillin and 200 μg/mL strepto-
mycin). Akata eGFP were additionally supplemented with 500 μg/ml
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lines 293 and 293T, the NPC cell line, C666-1, and the gastric
carcinoma cell line, SNU719 cells were cultured in Dulbeccos' modiﬁed
Eagle's medium (Invitrogen) supplemented with 10% FBS and
antibiotics (D10F). C666-1 cells were additionally grown on ﬁbro-
nectin. All cells were incubated in 5% CO2 at 37 °C. RNA was isolated
using TRIzol reagent (Invitrogen) as previously described (Chomc-
zynski and Sacchi, 1987). Total RNA was precipitated with linear
acrylamide (Ambion) as previously described (Gaillard and Strauss,
1990).
Induction of viral lytic replication in EBV-infected cell lines
Akata eGFP and the marmoset cell clone B958IID6 were induced to
support lytic replication of EBV. Akata eGFPwas treatedwith 10 μg IgG
per 2×10^6 cells at a concentration of 1×10^6 cells per mL for 1 h,
and then diluted to 5×10^5 cells per mL on day 0, and allowed to
grow in the presence of IgG for 4 days. B958IID6 cells were treated
with 20 μg/mL TPA and 35 mM sodium butyrate for four days. At each
timepoint, cells were counted, and a portion of the cells was harvested
for total RNA isolation and genomic DNA isolation. The remaining cells
were cultured between 7×10^5 and 1×10^6 cells per mL for the
duration of the induction.
Infection of primary B cells
Primary B cells were isolated from whole blood and infected with
recombinant B95-8 EBV and Akata EBV as previously described at a
multiplicity of infection (MOI) of 1 (Lee and Sugden, 2007).
Transformation of BART Cluster 1 and 2 into inducible BJAB cell clones
and induction of expression of miRNAs
Retroviral particles containing BART Cluster 1 or BART Cluster 2
vectors were generated in 293T cells as previously described (Lee and
Sugden, 2008). After 24 h, transfected 293T cells were irradiated at
3000 rads, and then BJAB cells engineered to express constitutively a
tet-KREB fusion protein were transduced by co-cultivation with the
293Tcells. Clones were selected for GFP expression, and then grown in
R10F +1 μg/mL puromycin.
To induce the expression of BART Cluster 1 or 2 miRNAs in BJAB
tet-KREB, the cells were cultured in R10F and treatedwith 10 ng/mL of
doxycycline for 96 h. Expression was conﬁrmed prior to harvesting
cells by the expression of GFP.
Transfection
293 cells were plated in 100-mm dishes and grown to ∼70%
conﬂuence. For each dish, 10 μg of vector was diluted in 500 μl of Opti-
MEM (Invitrogen) and then combined with pre-diluted Lipofecta-
mine-Opti-MEM (Invitrogen) mixture (30 μl of Lipofectamine diluted
in 500 μl of Opti-MEM, incubated 5 min at room temperature). DNA-
Lipofectamine complexes were incubated for 25 min at room
temperature. Cells were washed once with PBS and plated with
5 mL DMEM with 1 ml transfection mixture and incubated for 4 h at
37 °C at 5% CO2. Following the incubation, the medium was replaced
with 10 mL of fresh D10F. The transfection efﬁciency was determined
48 h later by counting GFP-positive cells and the RNA was isolated.
Western blotting
Cells were harvested and resuspended in a 1:1 volume of 1× NET
[50 mM Tris–HCl pH 7.4, 150 mM NaCl, 5 mM EDTA] and 2× Sample
Buffer [100 mM Tris pH 6.8, 10% SDS, 10% glycerol, 50 μl/mL
β-mercaptoethanol, 0.04% bromophenol blue]. Lysates were run on a
12% SDS-polyacrylamide gel electrophoresis (PAGE), transferred tonitrocellulose, and blocked overnight at 4 °C in BLOTTO [5% non-fat
milk (w/v), 0.075% Tween-20, 1× PBS]. Blots were probed with
primary antibody, followed by secondary antibody conjugated to
alkaline phosphatase (donkey anti-mouse at 1:1000, Jackson Labora-
tories). Bands were visualized using a solution of 5-bromo-4-chloro-
3′-indolyl phosphate p-toluidine salt and nitroblue tetrazolium
chloride. Western blots were scanned and quantiﬁed using Image-
Quant 5.2 software. Primary antibodies include: IH4 mouse mono-
clonal anti-EBNA-1 antibody at 1:50 and mouse monoclonal anti-α
tubulin antibody (Sigma-Aldrich) at 1:10,000.
Stem-loop real-time PCR
EBV BHRF1 and BARTmiRNAswere speciﬁcally reverse transcribed
using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosys-
tems). Stem-loop primers to the assayed miRNAs were designed in a
similar manner to those designed for reverse transcription of human
miRNAs (Chen et al., 2005). For each miRNA assayed, 200 ng of total
RNA was reverse transcribed as described by the manufacturer. For
measurements in primary B cells infected with Akata or B95-8 EBV,
10 ng of total RNA was used.
Each 20 μl PCR reaction contained 1.5 μM forward primer, 0.7 μM
reverse primer, 0.2 μM probe, and 1× TaqMan Universal Master Mix,
no UNGAmpErase (Applied Biosystems) as previously reported (Chen
et al., 2005). Probes were labeled with 5′ FAMRA and 3′ TAMRA. The
sequences of primers and probes are listed for each miRNA assayed
(Supplementary Table 1). Primers and probes for EBV miRNAs
were ordered from IDT (IDT DNA). A U38B kit was used to detect
the snoRNAU38B (Applied Biosystems). The reactions were incubated
in a 384-well plate at 50 °C for 2 min, 95 °C for 10 min, followed by 40
cycles of 95 °C for 15 s, and 54 °C for 1 min. The absolute copy number
of each miRNA in test samples was determined with reverse
transcription and ampliﬁcation of synthetic miRNAs identical to the
mature miRNA sequence as annotated in miRBase in March, 2008
(Grifﬁths-Jones, 2004; Grifﬁths-Jones et al., 2006, 2008). Synthetic
miRNAs were ordered from IDT (IDT DNA).
Measuring the precision of stem-loop real-time PCR
The method traditionally used to detect miRNAs, Northern blot, is
difﬁcult to render both sensitive and quantitative. We used a
quantitative method to detect and determine the levels of EBV's
miRNAs sensitively in various EBV-positive cell lines. Stem-loop
quantitative real-time PCR (qPCR) measures levels of single miRNAs
and can be rendered quantitative with standard curves, permitting
comparisons. This method has the added beneﬁt that it requires no
more than one-hundredth the RNA used for Northern blotting.
To gauge the precision of qPCR, we determined the standard
deviation for three different types of measurements. First, we mea-
sured the precision of triplicates from the same stem-loop reverse
transcription reaction for the snoRNA, U38B. U38B was recommended
as a constant cellular standard for stem-loop real-time PCR by Applied
Biosystems. The average standard deviation of the average number of
U38B molecules was 3%. We did not, however, ﬁnd the levels of U38B
to be the same in all cell lines. Rather, we found the levels to be the
greatest in the marmoset cell line, B958IID6, which contained
approximately 550 U38B molecules per 10 pg of RNA. In human cell
lines, the levels of U38B ranged from 355 to 145molecules per 10 pg of
RNA in KemI and 721 cells respectively, and the average U38B steady-
state levels were 246+/−64 molecules per 10 pg of RNA in all
assayed EBV-positive cell lines. Second, we measured the precision of
triplicate qPCR measurements from the same reverse transcription
reaction for the nine assayed EBV miRNAs, and found the average
standard deviation to be 9% and range between 0.3% and 32% of the
average molecules per 10 pg of RNA. Finally, for seven cell lines we
measured the levels of four EBV miRNAs twice from two independent
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experiments for EBV miRNAs was found to be 45% of the average
molecules per 10 pg of RNA. These results indicate that two-fold
differences measured between the quantities of miRNAs are within
the error of those measurements.Real-time PCR of EBERs
1 μg of total RNA was reverse transcribed with Superscript II RT
(Invitrogen) according to manufacturer's instructions using EBER-
speciﬁc reverse primers at a ﬁnal concentration of 0.5 μM and GAPDH
with oligo d(T) at a ﬁnal concentration of 5 μM. Reverse transcribed
cDNA was ampliﬁed and detected by qPCR under the following
conditions: 1× Amplitaq Gold PCR Master Mix (Applied Biosystems),
0.5 μM each primer, 0.2 μM probe, 1× ROX reference dye (Invitrogen)
andwater to 20 μl. PCR cycling conditionswere 50 °C for 2min, 95 °C for
10 min, and then 40 cycles of 95 °C for 15 s, and 60 °C for 60 s. The
following oligonucleotide sequences were used for RT-qPCR: GAPDH,
forwardprimer: 5′-TCAACGACCACTTTGTCAAGCT-3′, reverse primer:
5′-CCATGAGGTCCACCACCCT-3′, probe: 5′-TTCCTGGTATGACAACGA
ATT TGG CTA CAG C-3′, EBER1, forward primer: 5′-TTT GCT AGG GAG
GAG ACG TGT GT-3′, reverse primer: 5′-AAG CAG AGT CTG GGA AGA
CAA CCA-3′, probe: 5′-TAC AAG TCC CGG GTG GTG AGG A-3′, EBER2,
forward primer: 5′-TTG CCC TAG TGG TTT CGG ACA CA-3′, reverse
primer: 5′-AAT AGC GGA CAA GCC GAA TAC CCT-3′, and probe: 5′-TTC
CCG CCT AGA GCA TTT GCA AGT CA-3′. Probes were labeled with 5′
FAMRA and 3′ TAMRA.Fluorescent in situ hybridization
Fluorescent in situ hybridization (FISH) was performed on EBV-
positive and negative B cell lines as described previously (Nanbo
et al., 2007).Isolation of genomic DNA and quantiﬁcation of EBV genomes
Genomic DNA from cells induced to support the lytic replication of
EBV was isolated and quantiﬁed by qPCR as previously described
(Perrigoue et al., 2005). Brieﬂy, 10 ng of genomic DNA was ampliﬁed
and detectedwith primer-probe sets to the EBV gene, BALF5 (Forward:
5′-CGG AAG CCC TCT GGA CTT C-3′, Reverse: 5′-CCC TGT TTA TCC GAT
GGA ATG-3′, and Probe: 5′-TGT ACA CGC ACG AGA AAT GCG CC-3′), or
β-actin (Forward: 5′-TCACCCACACTGTGCCCATCTACGA-3′, Reverse:
5′-TCAGGTAGTCAGTCAGGTCCCG-3′, and Probe:5′-ATGCCCTCCCCC
ATG CCATCC TGCGT-3′) as a loading control. Probeswere labeledwith
5′ FAMRA and 3′ TAMRA. Genomes were quantiﬁed using a known
quantity of the HindIII D fragment of EBV's genomic sequence.Statistical methods
Statistical tests were performed using MStat 5.01 provided by
Norman Drinkwater (Drinkwater, 2008).Acknowledgments
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